<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081924</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/1807</org_study_id>
    <nct_id>NCT02081924</nct_id>
  </id_info>
  <brief_title>Reproductive Hormones During Sustained Administration of Kisspeptin</brief_title>
  <acronym>KisspeptPump</acronym>
  <official_title>Prospective Placebo-controlled Parallel Design Physiological Study of the Natural Hormone Kisspeptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the physiological effects of sustained
      administration of the natural hormone kisspeptin on reproductive function in participants
      with reduced fertility. Kisspeptin is a recently identified natural hormone which is
      regulates human reproduction. Learning more about the physiological role of kisspeptins may
      therefore give us a better understanding about human fertility, and improve the management of
      patients with reduced fertility. The effects of sustained administration of kisspeptin on
      hypothalamic reproductive function (i.e. Luteinising hormone pulsatility) are not known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive continuous administration of kisspeptin-54 or saline (placebo) for
      a maximum duration of 3 months, via a portable battery operated pump device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of sustained administration of the hormone kisspeptin on luteinising hormone pulsatility in participants with reduced fertility.</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether there is a difference in luteinising hormone pulsatility between normal fertility participants and reduced fertility participants when given sustained administration of the hormone kisspeptin.</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Fertility Disorders</condition>
  <condition>Hypothalamic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Kisspeptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive kisspeptin hormone or placebo via a subcutaneous pump device for up to 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive kisspeptin hormone or placebo via a subcutaneous pump device for up to 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kisspeptin</intervention_name>
    <description>Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.</description>
    <arm_group_label>Kisspeptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Aged 18-60 years old

          -  Ability to give informed consent

          -  Secondary hypogonadism (or healthy participant)

        Exclusion criteria:

          -  anaemia

          -  medical problems such as severe heart, kidney or liver disease

          -  blood donation in the last three months or intention to donate blood within 3 months
             of the end of the study

          -  needle phobia

          -  Poor venous access

          -  Active psychiatric illness

          -  Severe allergies

          -  Impaired ability to provide full consent to take part in the study

          -  Current alcohol or illicit drug dependence

          -  Current pregnancy or breast feeding

          -  Plans to conceive within 3 months of starting the study (barrier contraception must be
             used during and for 3 months after the end of the study)

          -  Arthritis or any impairment of hand coordination which would preclude using a hormone
             pump
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waljit Dhillo, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Channa Jayasena, MA PhD MRCP</last_name>
    <phone>020 8383 3242</phone>
    <email>c.jayasena@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College NHS Healthcare Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waljit Dhillo, PhD, FRCP</last_name>
      <phone>020 8383 3242</phone>
      <email>w.dhillo@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Channa Jayasena, MBBS, PhD</last_name>
      <phone>020 8383 3242</phone>
      <email>c.jayasena@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Waljit Dhillo, PhD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15. Epub 2005 Sep 20.</citation>
    <PMID>16174713</PMID>
  </reference>
  <reference>
    <citation>Dhillo WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson M, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donaldson M, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007 Oct;92(10):3958-66. Epub 2007 Jul 17.</citation>
    <PMID>17635940</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatei MA, Bloom SR, Dhillo WS. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009 Nov;94(11):4315-23. doi: 10.1210/jc.2009-0406. Epub 2009 Oct 9.</citation>
    <PMID>19820030</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Abbara A, Murphy KG, Lim A, Patel D, Mehta A, Todd C, Donaldson M, Trew GH, Ghatei MA, Bloom SR, Dhillo WS. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010 Dec;88(6):840-7. doi: 10.1038/clpt.2010.204. Epub 2010 Oct 27.</citation>
    <PMID>20980998</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewki A, Vaal ML, Sriskandarajah L, Murphy KG, Farzad Z, Ghatei MA, Bloom SR, Dhillo WS. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011 Dec;96(12):E1963-72. doi: 10.1210/jc.2011-1408. Epub 2011 Oct 5.</citation>
    <PMID>21976724</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Kisspeptin</keyword>
  <keyword>Reproductive hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothalamic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

